Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.30    0.00 (0.00%)
Bid:
1.20
Ask:
1.40
Spread: 0.20 (16.667%)
Market Cap: £20.87m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Update on CFO Appointment

29 Nov 2016 07:00

RNS Number : 3503Q
Genedrive PLC
29 November 2016
 

 

 

For release: 29 November 2016

 

genedrive plc ("genedrive" or the "Company")

 

Update on CFO Appointment

 

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, is pleased to announce that, following his appointment as Chief Financial Officer and a Director of the Company as announced on 21 September 2016, Matthew Fowler will join genedrive plc on 13 December 2016.

 

Matthew joins genedrive plc with over 15 years of experience in senior positions in the manufacturing, power and support services industries. Prior to joining genedrive plc, Matthew spent eight years as Group Financial Controller of Scapa Group plc, a multinational manufacturing AIM-quoted business. At Scapa Group plc, Matthew was responsible for shaping and managing finance within the Group as well as strategy development and other core processes.

 

Before joining Scapa Group plc, Matthew spent three years at British Nuclear Group as Finance Manager where he managed the corporate centre's finance team and was responsible for planning, reporting and accounting. Matthew trained and qualified in the audit department of Deloitte & Touche.

- Ends -

 

For further details please contact:

genedrive plc

David Budd: CEO +44 (0)161 989 0245

 

Peel Hunt LLP

James Steel +44 (0)207 418 8900

Oliver Jackson

 

Consilium Strategic Communications

Chris Gardner +44 (0)203 709 5700

Matthew Neal

Laura Thornton

genedrive@consilium-comms.com 

 

 

Notes to Editors

 

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF test have been launched in India and a Genedrive® HCV test has been successfully assessed by the Institut Pasteur, Paris.

 

genedrive plc was formerly Epistem plc and continues to provide contract research services to drug development companies under the Epistem brand name.

 

Further details can be found at: www.genedriveplc.com and www.genedrive.com 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAPGGGUGUPQGMR
Date   Source Headline
25th Jan 202111:35 amRNSHolding(s) in Company
25th Jan 202111:05 amRNSSecond Price Monitoring Extn
25th Jan 202111:00 amRNSPrice Monitoring Extension
18th Jan 202112:29 pmRNSHolding(s) in Company
18th Jan 20217:00 amRNSNotice of Results
30th Dec 202012:50 pmRNSResult of AGM
23rd Dec 202011:39 amRNSHolding(s) in Company
21st Dec 20202:48 pmRNSResponse to new COVID strain
17th Dec 20209:12 amRNSHolding(s) in Company
16th Dec 20209:05 amRNSSecond Price Monitoring Extn
16th Dec 20209:00 amRNSPrice Monitoring Extension
16th Dec 20207:00 amRNSNotification of intent to distribute in the USA
11th Dec 20207:00 amRNSConversion of Remaining Loan Notes
7th Dec 20207:00 amRNSAdditional Listing
3rd Dec 20207:00 amRNSAIHL hospital study completion
30th Nov 20207:00 amRNSBlock listing Interim Review
26th Nov 20204:41 pmRNSSecond Price Monitoring Extn
26th Nov 20204:35 pmRNSPrice Monitoring Extension
20th Nov 20207:00 amRNSHigh clinical accuracy in India study
17th Nov 20207:00 amRNSFinal Results
10th Nov 202011:05 amRNSSecond Price Monitoring Extn
10th Nov 202011:00 amRNSPrice Monitoring Extension
2nd Nov 20204:40 pmRNSSecond Price Monitoring Extn
2nd Nov 20204:35 pmRNSPrice Monitoring Extension
29th Oct 20207:00 amRNSNotice of Results
28th Oct 20204:41 pmRNSSecond Price Monitoring Extn
28th Oct 20204:36 pmRNSPrice Monitoring Extension
22nd Oct 20207:00 amRNSPoint-of-Care solution to detect SARS-CoV-2 virus
19th Oct 202012:44 pmRNSHolding(s) in Company
12th Oct 202011:18 amRNSHolding(s) in Company
9th Oct 20207:00 amRNSHolding(s) in Company
6th Oct 20207:00 amRNSHolding(s) in Company
1st Oct 20206:09 pmRNSHolding(s) in Company
30th Sep 20207:00 amRNSSouth African approval
28th Sep 20207:00 amRNSPartial Conversion of Loan Notes
25th Sep 20207:00 amRNSVerification with Beckman Coulter Life Sciences
21st Sep 20209:40 amRNSHolding(s) in Company
18th Sep 20202:06 pmRNSSecond Price Monitoring Extn
18th Sep 20202:01 pmRNSPrice Monitoring Extension
17th Sep 20209:27 amRNSHolding(s) in Company
16th Sep 20203:15 pmRNSHolding(s) in Company
16th Sep 20209:00 amRNSHolding(s) in Company
15th Sep 20201:12 pmRNSHolding(s) in Company
14th Sep 20204:40 pmRNSSecond Price Monitoring Extn
14th Sep 20204:35 pmRNSPrice Monitoring Extension
14th Sep 20207:00 amRNSHolding(s) in Company
4th Aug 20202:05 pmRNSSecond Price Monitoring Extn
4th Aug 20202:00 pmRNSPrice Monitoring Extension
4th Aug 20207:00 amRNSCollaboration to automate COVID-19 PCR testing
23rd Jul 202011:06 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.